NDC 82293-028-31 - Sacubitril and Valsartan
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 82293-028
- Requested NDC
- 82293-028-31
- Package NDCs from labels
- 82293-028-10, 82293-028-20, 82293-028-31, 82293-028-30
- Manufacturer
- American Health Packaging
- Effective date
- 2026-06-11
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Sacubitril and Valsartan - American Health Packaging | American Health Packaging | 2026-06-11 | HUMAN PRESCRIPTION DRUG LABEL |
| Sacubitril and Valsartan | Novugen Pharma (USA) LLC | Novugen Pharma Sdn. Bhd. | Aizant Drug Research Solutions Pvt. Ltd. | 2026-03-17 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 82293-028-10 | Sacubitril and Valsartan | 60 in 1 BOTTLE | TABLET, FILM COATED | 60 | 2 | |
| 82293-028-20 | Sacubitril and Valsartan | 180 in 1 BOTTLE | TABLET, FILM COATED | 180 | 2 | |
| 82293-028-30 | Sacubitril and Valsartan | 100 in 1 BOX, UNIT-DOSE | TABLET, FILM COATED | 100 | 2 | |
| 82293-028-31 | Sacubitril and Valsartan | 10 in 1 BLISTER PACK | TABLET, FILM COATED | 10 | 2 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 82293-028-10 | EA - Each | 82293-028 | c79db7ef-6cf9-4f85-beba-44537002412a | 1 | 2025-09-12 |
| 82293-028-20 | EA - Each | 82293-028 | 1f8f3ce9-93f1-4fb7-92c5-a6bb72eb1e4c | 1 | 2025-09-12 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.